Evidence map›Paper›PMID 38914475›Full record

ArticleSexually transmitted infections2024

Multiple risk factors for persistent HBV viraemia in an adult receiving nucleos/tide analogue therapy.

Sheila Lumley, Maeve Barlow, Khadija Said, Emily Martyn, Elizabeth Waddilove, Marion Delphin, Daisy Jennings, Haiting Chai, Agnes Kemper, Joy Ko and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Sexually transmitted infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sheila LumleyNuffield Departmnet of Medicine, University of Oxford, Oxford, UK sheila.lumley@trinity.ox.ac.uk.ORCID 0000-0001-6825-9324
Maeve BarlowCentral North West London NHS Foundation Trust, London, UK.
Khadija SaidFrancis Crick Institute, London, UK.ORCID 0000-0001-7467-7290
Emily MartynFrancis Crick Institute, London, UK.
Elizabeth WaddiloveFrancis Crick Institute, London, UK.
Marion DelphinFrancis Crick Institute, London, UK.
Daisy JenningsNuffield Departmnet of Medicine, University of Oxford, Oxford, UK.
Haiting ChaiNuffield Departmnet of Medicine, University of Oxford, Oxford, UK.
Agnes KemperCentral North West London NHS Foundation Trust, London, UK.
Joy KoCentral North West London NHS Foundation Trust, London, UK.
Azim AnsariNuffield Departmnet of Medicine, University of Oxford, Oxford, UK.
Douglas MacdonaldRoyal Free Hospital, London, UK.
Indrajit GhoshCentral North West London NHS Foundation Trust, London, UK.
Samreen IjazVirus Reference Department, National Infection Service, UK Health Security Agency-Colindale, London, UK.
Stuart FlanaganCentral North West London NHS Foundation Trust, London, UK.ORCID 0000-0003-1545-8615
Philippa Clare MatthewsCentral North West London NHS Foundation Trust, London, UK.ORCID 0000-0002-4036-4269

Funding

Cancer Research UK CC2223Wellcome Trust 102176Wellcome Trust 110110
6 · The paper itself

Abstract

Diagnosing and treating chronic hepatitis B virus (HBV) infection are key interventions to support progress towards elimination of viral hepatitis by 2030. Although nucleos/tide analogue (NA) therapy is typically highly effective, challenges remain for viral load (VL) suppression, including medication access, incomplete adherence and drug resistance. We present a case of a long-term HBV and HIV coinfected adult prescribed with sequential NA therapy regimens, with episodes of breakthrough viraemia. Multiple factors contribute to virological breakthrough, including exposure to old NA agents, initial high HBV VL, therapy interruptions, intercurrent illnesses and potential contribution from resistance mutations. The case underscores the importance of individualised treatment approaches and adherence support in achieving HBV suppression. Furthermore, it emphasises the need for improved clinical pathways addressing education, support and access to care, particularly for marginalised populations. Comprehensive data collection inclusive of under-represented individuals is crucial for maintaining retention in the care cascade and informing effective interventions.

Indexed as

Antiviral AgentsHepatitis B, ChronicHepatitis B virusHIV InfectionsViral LoadViremiaAdultCoinfectionDrug Resistance, ViralGuanineHumansMiddle AgedRisk FactorsAntiviral AgentsGuanineAntiviral AgentsHEPATITIS BRESISTANCETHERAPY

Identifiers

PMID38914475
PMCPMC7617237

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.